KRAS and non-small cell lung carcinoma: Accordingly, the authors have highlighted that SHP2 inhibition promotes a senescence response in KRAS-mutant NSCLC cells, suggesting a rationale for targeting SHP2 in NSCLC harboring KRAS mutations.